VKTX VIKING THERAPEUTICS INC
2026Q2 · CUSIP 92686J106 · GLP-1 / Weight Loss · Sector: Healthcare & Biotech
Fund flows are within the usual range
435 funds held VKTX at the end of 2026Q2, up 22 from the quarter before. Fund flows are within the usual range — nothing unusual. On the business itself, revenue over the last 12 months was $0, return on equity is -131.0%. VKTX has had 11 buying rushes in its history, and the price moved -1.8% on average over the six months after (that is the raw price move, not how much it beat the market by). It sits in the Healthcare & Biotech sector, tagged GLP-1 / Weight Loss.
How many funds owned it, quarter by quarter
Bars = net change in institutional holders, positive (green) or negative (red). Line = total institutional holders.
What happened after each past buying rush 11 times in its history
| Quarter of the rush | How unusual then | Price, next 3 months | Price, next 6 months |
|---|---|---|---|
| 2025Q4 | Top 10% | +8.4% | -5.3% |
| 2025Q2 | Top 20% | -33.8% | -7.1% |
| 2024Q3 | Top 10% | -13.4% | -30.6% |
| 2024Q2 | Top 20% | +14.1% | -5.5% |
| 2024Q1 | Top 1% in the market | -23.5% | -0.6% |
| 2023Q1 | Top 5% | -35.8% | -42.1% |
| 2022Q4 | Top 20% | +49.0% | +102.6% |
| 2018Q4 | Top 20% | +12.8% | -7.6% |
These are the raw price moves, not how much it beat the market by. Compare them against the market over the same months — in a strong bull market almost everything is up.
Show all the numbers (large funds, value held, options…) ▾ Collapse ▴
These are for people who want to dig. Skip them if they do not mean anything to you — the three numbers above are enough.
Fundamentals
Quarterly figures, revenue up to 10 years back; EPS split-adjusted, early quarters hidden when not calibrable
As of 2026-06-30 · SEC filings (XBRL)
Email me the next update
2026 Q3 holdings are due 2026-11-16. We will email you when the refreshed lists are live.